Comment on ​Pending ovarian cancer drug news from ImmunoGen could be a turning point

​Pending ovarian cancer drug news from ImmunoGen could be a turning point

Ask ImmunoGen CEO Dan Junius why an experimental drug called IMGN853 is important for the company, and he will tell you it’s the company’s best shot at having a wholly-owned medicine on the market in coming years. But ask him why it’s important for patients with ovarian cancer, and he will cite some striking statistics. While development of cancer drugs has come a long way in the past 10 years, most of the advancements have been in blood cancers.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News